Abdominal obesity-metabolic syndrome (AOMS) is also known as syndrome X or insulin resistance syndrome. Insulin resistance is a key abnormality associated with an atherogenic, prothrombotic, and inflammatory profile. The most prevalent form of this constellation of metabolic abnormalities is found in patients with abdominal obesity, especially with an excess of intra-abdominal or visceral adipose tissue. Recently, a few causative gene mutations have been reported.
Keramati AR, Fathzadeh M, Go GW, Singh R, Choi M, Faramarzi S, Mane S, Kasaei M, Sarajzadeh-Fard K, Hwa J, Kidd KK, Babaee Bigi MA, Malekzadeh R, Hosseinian A, Babaei M, Lifton RP, Mani A
タイトル
A form of the metabolic syndrome associated with mutations in DYRK1B.
Esteghamat F, Broughton JS, Smith E, Cardone R, Tyagi T, Guerra M, Szabo A, Ugwu N, Mani MV, Azari B, Kayingo G, Chung S, Fathzadeh M, Weiss E, Bender J, Mane S, Lifton RP, Adeniran A, Nathanson MH, Gorelick FS, Hwa J, Sahin-Toth M, Belfort-DeAguiar R, Kibbey RG, Mani A
タイトル
CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation.
